WO2008114505A1 - Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant - Google Patents
Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant Download PDFInfo
- Publication number
- WO2008114505A1 WO2008114505A1 PCT/JP2008/000617 JP2008000617W WO2008114505A1 WO 2008114505 A1 WO2008114505 A1 WO 2008114505A1 JP 2008000617 W JP2008000617 W JP 2008000617W WO 2008114505 A1 WO2008114505 A1 WO 2008114505A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- agent
- treatment
- cell proliferative
- inhibitor
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001944 cysteine derivatives Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un inhibiteur d'Eg5 contenant un dérivé de cystéine représenté par la formule (I) ci-dessous ou un sel pharmacologiquement acceptable de celui-ci en tant qu'un ingrédient actif. La présente invention concerne également un agent destiné au traitement des troubles de la prolifération cellulaire. [formule chimique 1] (I) (Dans la formula, Ar représente un groupe aryle substitué ou non substitué ou un groupe hétérocyclique aromatique substitué ou non substitué ; R1 représente un atome d'hydrogène ou un groupe de protection d'un groupe amino ; et R2 et représente un groupe hydroxy, un groupe alcoxy, un groupe amino, un groupe -NH(CH2)2O(CH2)2NH2 ou équivalents. A cet égard, lorsque Ar est un groupe phényle, R2 est un groupe autre qu'un groupe hydroxy.)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009505077A JPWO2008114505A1 (ja) | 2007-03-16 | 2008-03-17 | Eg5阻害剤および該化合物を含有してなる細胞増殖性疾患治療薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007069487 | 2007-03-16 | ||
JP2007-069487 | 2007-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008114505A1 true WO2008114505A1 (fr) | 2008-09-25 |
Family
ID=39765623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/000617 WO2008114505A1 (fr) | 2007-03-16 | 2008-03-17 | Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008114505A1 (fr) |
WO (1) | WO2008114505A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
CN103740648A (zh) * | 2013-11-20 | 2014-04-23 | 成都正能生物技术有限责任公司 | 一种纺锤体驱动蛋白(Eg5)单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US9902690B2 (en) | 2013-12-27 | 2018-02-27 | Novus International, Inc. | Ethoxylated surfactants |
US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007104011A2 (fr) * | 2006-03-08 | 2007-09-13 | University Of Maryland, Baltimore | Inhibition de protrusion de microtubule dans des cellules cancereuses |
-
2008
- 2008-03-17 JP JP2009505077A patent/JPWO2008114505A1/ja active Pending
- 2008-03-17 WO PCT/JP2008/000617 patent/WO2008114505A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007104011A2 (fr) * | 2006-03-08 | 2007-09-13 | University Of Maryland, Baltimore | Inhibition de protrusion de microtubule dans des cellules cancereuses |
Non-Patent Citations (5)
Title |
---|
DEBONIS S. ET AL.: "STRUCTURE-ACTIVITY RELATIONSHIP OF S-TRITYL-L-CYSTEINE ANALOGUES AS INHIBITORS OF THE HUMAN MITOTIC KINESIN EG5", J. MED. CHEM., vol. 51, no. 5, 13 March 2008 (2008-03-13), pages 1115 - 1125 * |
KESSEL D. ET AL.: "EFFECTS OF S-(TRITYL)-L-CYSTEINE AND ITS ANALOGS ON CELL SURFACE PROPERTIES OF LEUKEMIA L1210 CELLS", BIOCHEM. PHARMACOL., vol. 25, no. 16, 1976, pages 1893 - 1897, XP023729552, DOI: doi:10.1016/0006-2952(76)90195-7 * |
OGO N. ET AL.: "SYNTHESIS AND BIOLOGICAL EVALUATION OF L-CYSTEINE DERIVATIVES AS MITOTIC KINESIN EG5 INHIBITORS", BIOORG. MED. CHEM. LETT., vol. 17, no. 14, 15 July 2007 (2007-07-15), pages 3921 - 3924, XP022119981 * |
ZEE-CHENG K.Y. ET AL.: "EXPERIMENTAL ANTILEUKEMIC AGENTS. PREPARATION AND STRUCTURE-ACTIVITY STUDY OF S-TRITYLCYSTEINE AND RELATED COMPOUNDS", J. MED. CHEM., vol. 13, no. 3, 1970, pages 414 - 418, XP002919020 * |
ZEE-CHENG K.Y. ET AL.: "STRUCTURAL MODIFICATION OF S-TRITYL-L-CYSTEINE. PREPARATION OF SOME S-(SUBSTITUTED TRITYL)-L-CYSTEINES AND DIPEPTIDES OF TRITYL-L-CYSTEINE", J. MED. CHEM., vol. 15, no. 1, 1972, pages 13 - 16, XP002398931 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
CN103740648A (zh) * | 2013-11-20 | 2014-04-23 | 成都正能生物技术有限责任公司 | 一种纺锤体驱动蛋白(Eg5)单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
CN103740648B (zh) * | 2013-11-20 | 2016-08-31 | 成都汇瑞新元生物科技有限责任公司 | 一种纺锤体驱动蛋白(Eg5)单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
US9902690B2 (en) | 2013-12-27 | 2018-02-27 | Novus International, Inc. | Ethoxylated surfactants |
US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008114505A1 (ja) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1921077A4 (fr) | Agent de traitement et/ou de prevention des troubles du sommeil | |
WO2008114812A1 (fr) | Inhibiteur de jak | |
WO2008111441A1 (fr) | Composition pharmaceutique | |
WO2008126901A1 (fr) | Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant | |
WO2008087933A1 (fr) | Nouveau dérivé d'indole ayant une activité inhibitrice sur la iκb kinase β | |
WO2005095395A3 (fr) | Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives | |
WO2009069736A1 (fr) | Composé azoté | |
TW200616994A (en) | Novel thiophene derivatives | |
WO2005097129A3 (fr) | Compose de 6-azaindole | |
MY146532A (en) | Thiazole derivative | |
GB2442148A (en) | FK 228 derivates as HDAC inhibitors | |
AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
WO2007082808A3 (fr) | Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1 | |
WO2008108386A1 (fr) | Composition pharmaceutique | |
WO2007095174A3 (fr) | derives d'acides biliaires en tant que ligands de FXR pour la prevention ou le traitement de maladies ou d'etats induits par FXR | |
WO2007122634A3 (fr) | Inhibiteurs de kinase | |
MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
MX2009005691A (es) | Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i. | |
WO2005012269A8 (fr) | Nouveau compose azole | |
WO2008108378A3 (fr) | Dérivé bicyclique d'oxomorpholine | |
EP1867331A4 (fr) | Dérivé de triazole et utilisation de celui-ci | |
GEP20104875B (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
EP1854789A4 (fr) | Derive de quinazoline possedant une activite inhibitrice vis-a-vis de la tyrosine kinase | |
MX2010001566A (es) | Derivado de aminopirazolamida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08720502 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009505077 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08720502 Country of ref document: EP Kind code of ref document: A1 |